Skip to contentR
Revolution Medicines, Inc.
R
RVMDWRevolution Medicines, Inc. Q3 2024 · 10-Q
Revenue$0.00$0.00— vs Q3 2023 Net Income-$156.29M-$156.29MN/M vs Q3 2023 EPS Diluted-$0.94-$0.94N/M vs Q3 2023 Operating Income-$175,712,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$133,939,000N/M ended Sep 30, 2024 · filed Nov 6, 2024 · 37 d after period end